Key result
Platelet aggregation after stimulation with ADP resulted in 24% additional FXIIIa release compared to platelet-poor plasma, correlating with maximal plasma clot strength.
Why the study?
Does in vitro platelet stimulation with ADP release factor XIIIa and correlate with clot strength in CAD patients on dual antiplatelet therapy?
Observational (n=96)
Does in vitro platelet stimulation with ADP release factor XIIIa and correlate with clot strength in CAD patients on dual antiplatelet therapy?
Platelets from CAD patients on aspirin and clopidogrel release significant FXIIIa upon ADP aggregation, which correlates with increased plasma clot strength.
Answers are grounded in this paper and cite their sources.
Platelet FXIIIa release may strengthen clots; leaves open whether modulating this pathway affects clinical hemostasis or thrombosis.
It has been estimated that up to half of circulating factor XIIIa (FXIIIa) is stored in platelets. The release of FXIIIa from platelets upon stimulation with adenosine diphosphate (ADP) in patients with coronary artery disease treated with dual antiplatelet therapy has not been previously examined. Samples from 96 patients with established coronary artery disease treated with aspirin and clopidogrel were examined. Platelet aggregation was performed by light transmittance aggregometry in platelet-rich plasma (PRP), with platelet-poor plasma (PPP) as reference, and ADP 5 µM as agonist. Kaolin-activated thrombelastography (TEG) was performed in citrate PPP. PRP after aggregation was centrifuged and plasma supernatant (PSN) collected. FXIIIa was measured in PPP and PSN. Platelet aggregation after stimulation with ADP 5 µM resulted in 24% additional FXIIIa release in PSN as compared to PPP (99.3 ± 27 vs. 80.3 ± 24%, p < 0.0001). FXIIIa concentration in PSN correlated with maximal plasma clot strength (TEG-G) (r = 0.48, p < 0.0001), but not in PPP (r = 0.15, p = 0.14). Increasing quartiles of platelet-derived FXIIIa were associated with incrementally higher TEG-G (p = 0.012). FXIIIa release was similar between clopidogrel responders and non-responders (p = 0.18). In summary, platelets treated with aspirin and clopidogrel release a significant amount of FXIIIa upon aggregation by ADP. Platelet-derived FXIIIa may contribute to differences in plasma TEG-G, and thus, in part, provide a mechanistic explanation for high clot strength observed as a consequence of platelet activation. Variability in clopidogrel response does not significantly influence FXIIIa release from platelets.
No takes yet. Share an insight, caveat, or question.
Kreutz et al. (2014) conducted an observational in Coronary artery disease (n=96). Platelet aggregation after stimulation with ADP vs. Platelet-poor plasma (PPP) was evaluated on Factor XIIIa (FXIIIa) release (p=< 0.0001). Platelet aggregation after stimulation with ADP resulted in 24% additional FXIIIa release compared to platelet-poor plasma, correlating with maximal plasma clot strength.
Synapse has enriched 10 related papers. Consider them for comparative context: